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TreatmentErythema nodosum leprosum (ENL) is a common complication of lepromatous leprosy.
Some patients unresponsive to conventional, first-line therapeutics develop recurrent,
recalcitrant ENL. Here, we report a case of severe refractory ENL that was successfully
treated with Etanercept. Biologics may be considered as therapeutic alternatives in
management of severe, recalcitrant ENL.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Case Report
Leprosy (LR) is a chronic infectious disease caused by
Mycobacterium leprae. It is primarily a disease of the peripheral
nervous system and skin, but other organs may also be
involved. Erythema nodosum leprosum (ENL), the most
common manifestation of type 2 LR (T2LR), is an immune
complex–mediated complication of lepromatous leprosy (LL).
T2LRpresentswith skin lesions (red,painful, and tender subcu-
taneous lesions), fever, and systemic inflammation that may
affect the nerves, eyes, joints, testes, and lymph nodes [1].
Althoughmild episodes of ENL can be treated symptomaticallywith anti-inflammatory agents [non-steroidal anti-inflammatory
drugs (NSAIDS)] and usually resolve spontaneously, more severe
cases (i.e., those with nerve involvement or systemic involve-
ment) require systemic therapy, such as steroids and Thalido-
mide, to manage the reactional state of the disease and prevent
permanent residual complications.
Here, we present a patient with severe ENL who was suc-
cessfully treated with Etanercept, a tumor necrosis factor
alpha (TNF-a) inhibitor; as he was refractory to treatment
with conventional therapies.
A 49-year-old man diagnosed as a case of nodular LL (in his
2nd month of multidrug anti-leprosy treatment) and diabetesiences and
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1-week history of erythematous, tender papules, and nodules
over his forearms, trunk, thighs, buttock, and calves,
accompanied by high-grade fever, myalgia, and inguinal
lymphadenopathy. He also had severe neuritis of the ulnar
and radial cutaneous nerve. Laboratory investigations showed
increases in total leukocyte count (16,000/mm3), anemia
(hemoglobin: 9 g/dl), raised erythrocyte sedimentation rate
(36 mm/h), random blood sugar (178 mg/dL), elevated TNF-a
(19 pg/mL) and interleukin 6 (IL6; 4 pg/mL). Slit skin smears
from all three sites (eyebrows, ear lobes, and skin nodules)
showed solid stained acid-fast bacilli, with few fragmented
and granular acid-fast bacilli, arranged in globi (Fig. 1).
Therefore, our final grading of the bacteriological index was
6+, and the skin biopsy from one of the nodules was consis-
tent with ENL.
After making a diagnosis of severe ENL, the patient
received oral Prednisolone (40 mg) in addition to his anti-
leprosy multidrug therapy (MDT), comprised of 600 mg of
monthly Rifampicin, 300 mg monthly of Clofazimine, 100 mg
Dapsone, and 50 mg Clofazimine daily. Supportive treatment
in the form of NSAIDS and multivitamins was also instituted.
However, after initial improvement following Prednisolone
treatment for 2 weeks, the patient again developed new ten-
der erythematous lesions of ENL associated with malaise
and fever. Over the next 6 months, despite multiple extended
courses of Prednisolone in higher doses (40–80 mg daily),
Clofazimine (300 mg daily), Thalidomide (starting dose:
300 mg daily), Minocycline (100 mg daily), Clarithromycin
(1 g daily), Ofloxacin (400 mg daily), Pentoxifylline (400 mg
three times daily), and Azathioprine (150 mg daily; later
increased to 300 mg), the patient had few symptom-free peri-
ods and experienced many ENL-related episodes with
increased severity of lesions in the form of numerous necroticFig. 1 – Globi arrangement of acid-fast lepra bacilli.lesions (Fig. 2, neuritis, and severe systemic manifestations,
including epididymo-orchitis and lymphadenitis.
The patient developed adverse effects, such as oral can-
didiasis, abdominal pain, and diarrhea due to above-
mentioned medications. There was aggravation of peripheral
neuropathy after starting Thalidomide, which was then dis-
continued. He also developed uncontrolled diabetes mellitus
and hypertriglyceridemia (670 mg/dL) due to prolonged ster-
oid therapy. These complications were not only difficult to
manage, but they were aggravated with medication for ENL.
Given the severity of patient symptoms despite the use of
standard therapies, alternative management strategies were
considered, andwe decided to start the patient on Etanercept.
Before starting Etanercept, the patient underwent a series of
investigations to rule out any underlying immunosuppression
or latent foci of tuberculosis in the form of a Mantoux test,
chest X-ray, interferon-gamma release assay, and Hepatitis
B and HIV serologies. Since there was no abnormality
detected in any of the above-mentioned investigations,
Etanercept was administered in a dose of 50 mg/week subcu-
taneously. The patient showed signs of improvement within
48 h of the first dose in the form of decreases in constitutionalFig. 2 – Multiple deep punched-out necrotic ulcers of
erythema nodosum leprosum.
Fig. 3 – Healed lesions of ENL with post inflammatory
hyperpigmentation ENL = erythema nodosum leprosum.
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lesions. After receiving Etanercept for 12 weeks, the patient
improved significantly (Fig. 3), allowing for a slow taper and
eventual discontinuation of Prednisolone.
The patient was continued on 50 mg/week Etanercept
(thirteenth dose of injection) and MDT and consequently did
not have a recurrence of ENL. After 16 weekly injections of
Etanercept, we proposed tapering the dose to biweekly and
gradually discontinued the same over a period of time.
The underlying immunopathological mechanism for ENL
remains unclear. ENL has traditionally been considered an
immune complex–mediated phenomenon with an accompa-
nying vasculitis [2–4]. However, high levels of TNF-a and IL6
are consistently found in patients with more severe forms
of the disease, suggesting that a cell-mediated immuneresponse also plays a role [5]. This provided the rationale for
the use of TNF-inhibitory agents reported by Faber et al.
(who used Infliximab) [6] and Ramien et al. (who used Etaner-
cept) [7] when conventional therapies were not sufficient to
control symptoms.
Since Etanercept is less costly, has better patient conve-
nience (comes in self-administered injections), and causes
less immunosuppression relative to Infliximab, we chose to
treat our patient with Etanercept.
The impressive clinical response of our patient to
Etanercept, along with similar reports by Faber et al. [6] and
Ramien et al. [7] to Infliximab and Etanercept, respectively,
provided additional evidence to support an important role
of TNF-a in the pathogenesis of severe ENL, as well as
established them as promising treatments for these patients.
However, utmost care should be taken to look for reactivation
of tuberculosis and immunosuppression. Further research to
determine the role of TNF-a in the pathogenesis of ENL is
needed. In conjunction, randomized controlled trials are nec-
essary to establish the role of inhibition of TNF-a in treating
patients who have severe recalcitrant ENL that is unrespon-
sive to standard conventional therapy.
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